Evaluation of Dupilumab in Patients With Bullous Pemphigoid

Liuqi Zhao,Qijun Wang,Guirong Liang,Yuxi Zhou,Nam Yiu,Baoqi Yang,Guiying Zhang,Wei Li,Suying Feng,Panpan Shang,Xixue Chen,Xuejun Zhu,Jie Zheng,Meng Pan,Mingyue Wang

DOI: https://doi.org/10.1001/jamadermatol.2023.2428

IF: 11.816

2023-09-21

JAMA Dermatology

Abstract:This retrospective cohort study assesses the patient outcomes and safety of dupilumab in adults with bullous pemphigoid.

dermatology

What problem does this paper attempt to address?

Long-term efficacy and safety of dupilumab for severe bullous pemphigoid: A prospective cohort study

Dawei Huang,Yuexin Zhang,Yingyuan Yu,Yuxiong Jiang,Luyang Kong,Yangfeng Ding,Yuling Shi,Yunlu Gao

DOI: https://doi.org/10.1016/j.intimp.2023.111157

Abstract:Background: Bullous pemphigoid (BP) is a common subepidermal bullous disease. Dupilumab is a novel treatment for BP. However, its long-term efficacy and safety have not been demonstrated in prospective studies. Objective: Evaluate the long-term efficacy and safety of dupilumab in treating severe BP. Methods: Patients were divided into two groups: the methylprednisolone monotherapy group (M), and the methylprednisolone and dupilumab combination therapy group (D + M). This study consisted of two stages. The first stage focused on the initial treatment phase, where the early efficacy and safety was evaluated. The study then entered the 12-month maintenance treatment stage, where we assessed recurrence in both groups. Additionally, we evaluated the rate of healing of skin lesions, glucocorticoids burden and length of hospital stay and various laboratory test indicators. Results: After four weeks of treatment, the Bullous Pemphigoid Disease Area Index (BPDAI) and pruritus Numerical Rating Scale scores of the D + M group decreased significantly more than those of the M group. The median BPDAI at week 4 was 0 (range: 0.0-3.0) in the D + M group and 10.0 (5.0-12.0) in the M group (P < 0.001). Patients treated with dupilumab experienced a faster cessation of new blisters, quicker glucocorticoid reduction, shorter healing times, and shorter hospital stays (P < 0.001). Additionally, after two weeks of treatment, the levels of eosinophils and immunoglobulin E also decreased (P < 0.001). Follow-up studies further demonstrated that dupilumab monotherapy was associated with a lower recurrence rate. Notably, no serious adverse effects were observed in the study. Conclusions: Our study provides evidence for the efficacy of dupilumab in the treatment of BP based on prospective studies. Additionally, our findings suggest that dupilumab can be considered a reliable single-agent maintenance treatment due to its good safety profile and lower relapse.
Efficacy and safety of dupilumab in the treatment of 21 cases of bullous pemphigoid: a retrospective study

赵柳琦,陈妍,陈丹阳,樊碧娆,王瑞,尚盼盼,陈喜雪,朱学骏,王明悦

DOI: https://doi.org/10.35541/cjd.20210813

2022-01-01

Chinese Journal of Dermatology

Abstract:Objective:To retrospectively analyze the efficacy and safety of dupilumab in the treatment of bullous pemphigoid (BP) .Methods:Clinical data were collected from BP patients who received injections of dupilumab at an initial dose of 600 mg followed by an every-2-week regimen at a dose of 300 mg (the frequency of injections could be increased if necessary) in Department of Dermatology, Peking University First Hospital from October 2020 to October 2021, and their clinical manifestations and changes in laboratory indices were analyzed.Results:A total of 21 BP patients treated with dupilumab were included in this study. Nineteen (90.5%) patients achieved complete or marked disease control after 2-week treatment with dupilumab; 12 patients were followed up for 16 weeks, and all maintained complete disease control at 16 weeks. All patients had a bullous pemphigoid disease area index (BPDAI) score of 122.5 ± 51.1 points at baseline, which decreased to 30.6 ± 27.4 points after 2-week treatment with dupilumab ( t = 8.53, P < 0.001) , and continued to decrease to 12.7 ± 9.1 points after 4-week treatment ( t = 9.73, P < 0.001) . Pruritus was markedly relieved in all the 21 patients within 4-week treatment with dupilumab. Among 10 patients with elevated eosinophil counts at baseline, the eosinophil counts markedly decreased in 9 after treatment. The serum IgE level was elevated in 7 patients at baseline, which markedly decreased in 6 after treatment. Viral conjunctivitis occurred in 1 (4.8%) patient, and no adverse reactions were observed in other patients. Conclusion:Dupilumab is effective in the control of BP and relief of pruritus, with a favorable safety profile.
A Systematic Evaluation of Dupilumab for Bullous Pemphigoid Treatment

Shengzhen Ye,Guihua Ling,Mingling Chen

DOI: https://doi.org/10.1155/2024/1171779

2024-04-27

Dermatologic Therapy

Abstract:This paper systematically reviews the current articles regarding the use of dupilumab in the treatment of bullous pemphigoid (BP) to evaluate its safety and efficacy. PubMed, Embase, Cochrane Library, and Web of Science databases were searched for publications on dupilumab for BP from inception to 10 March, 2023. A total of 26 studies were included for systematic review. The primary outcome was clinical remission, and the secondary outcomes were recurrence and adverse events. Among 96 patients, 71.8% (n = 69/96) received systemic or topical steroids, immunosuppressants, immunomodulators, intravenous immunoglobulins, antihistamines, plasmapheresis, rituximab, and omalizumab, but none of them were successful. After dupilumab treatment, 66.7% (n = 64/96) of patients achieved complete remission, 25.0% (n = 24/96) had partial remission, 5.2% (n = 5/96) showed no remission, and no patients experienced deterioration. In addition, 1.0% (n = 1/96) and 2.0% (n = 2/96) patients stopped using dupilumab due to adverse reactions and cost, respectively. The average remission time was 4.5 months. 46.2% (n = 25/96) of the patients were followed up with a median follow-up of 8 months and only 2 patients relapsed at 8 and 7 months, respectively. Adverse event was 16.9% (n = 12/71), of which transient eosinophilia was the most common. This study indicates that the dupilumab is a promising treatment for BP with high clinical benefit associated with low recurrence rate, adverse event rate, and mortality. However, a large-scale randomized controlled trial is needed to further confirm the safety and efficacy of dupilumab in patients with BP treatment.

dermatology
Real-World Evaluation of the Effectiveness and Safety of Dupilumab in Bullous Pemphigoid: An Ambispective Multicenter Case Series

Nidia Planella-Fontanillas,Xavier Bosch-Amate,Alicia Jiménez Antón,Carlos Moreno-Vílchez,María Gamo Guerrero,María Del Mar Blanes Martínez,M Asunción Ballester Martínez,Patricia Bassas-Freixas,Juan Luis Castaño Fernández,Andrea Estébanez Corrales,Ricardo Suarez Fernández,Sergio Santos Alarcón,Ana Bauzá Alonso,Marina Torrent,Adrian Ballano Ruiz,Cristina Collantes Rodríguez,Agustín España,Eduardo Fonseca Capdevila,Inmaculada Gil Faure,Carlos Pelayo Hernández Fernández,Francisco Javier Melgosa Ramos,Jorge Spertino,Violeta Zaragoza Ninet,Lucia Armillas,Isabel Bielsa,Cristina Carrera,Mireia Esquius Rafat,Jon Fulgencio Barbarin,Javier Fernandez Vela,Miguel Lova Navarro,Clara Martín Callizo,Sara Martín-Sala,Rosa Ojeda,Maria Elisabet Parera Amer,Anna Sánchez Puigdollers,Ramon M Pujol,Sebastian Podlipnik,José Manuel Mascaró Jr,Laia Curto-Barredo

DOI: https://doi.org/10.1093/bjd/ljae403

2024-10-17

Abstract:Background: Bullous pemphigoid affects elderly individuals with multiple comorbidities, making conventional treatments unsuitable. Objective: Evaluate the effectiveness and safety of dupilumab in the treatment of bullous pemphigoid. Methods: A multicenter ambispective cohort study was conducted in 34 hospitals. Patients with bullous pemphigoid treated with Dupilumab were included. Most of patients (97.1%) received an initial 600 mg dose followed by 300 mg every two weeks. Outcomes and measures: The primary outcome was the proportion of patients achieving complete remission within 4 weeks, defined as Investigator Global Assessment score of 0 or 1. Complete remission at weeks 16, 24, and 52, adverse events, reductions in peak pruritus numerical rating scale, and systemic glucocorticoid use were also assessed. Results: The study included 103 patients with a median age of 77.3 years, 58.0% male. Complete remission was achieved by 53.4% within 4 weeks and 95.7% by week 52. Peak pruritus scale reduced by 70.0% by week 4 and was completely controlled by week 24. Thirteen patients presented adverse events, most of which were mild. Systemic glucocorticoid use reduced by 82.1% by week 52. Shorter disease duration and exclusive cutaneous involvement predicted better response at 16 weeks. No differences in response rates to dupilumab were observed between drug-associated bullous pemphigoid and idiopathic cases. No significant difference in response rates was observed between patients treated with dupilumab in monotherapy and those receiving dupilumab with concomitant treatments. Conclusions: Dupilumab is effective, rapid, and safe in managing bullous pemphigoid, reducing the need for corticosteroids and other treatments. Early initiation and exclusive skin involvement predict better outcomes.
Concomitant use of dupilumab with glucocorticoid in bullous pemphigoid reduces disease severity: A preliminary study

Lingyu Hu,Ruiting Huang,Fuqiong Jiang,Shuqiong You,Qian Wu

DOI: https://doi.org/10.1002/iid3.924

Abstract:Objective: To retrospectively analyze the efficacy and safety of dupilumab in the treatment of bullous pemphigoid. Methods: From October 2020 to October 2022, the medical records of patients with bullous pemphigoid who were treated with dupilumab in our department were collected retrospectively to analyze the therapeutic effect and changes in laboratory indexes. Results: The records of a total of 11 patients with bullous pemphigoid who were treated with dupilumab was reviewed. Within 2 weeks of the treatment, 10 (90.9%) of the 11 patients had complete or substantial control of the disease. The BPDAI scores of the patients decreased from baseline 113 (62, 181) to 37 (6, 130) at 2 weeks (p = .001) and 4 (0, 37) at 12 weeks after treatment (p < .001). In the 11 patients treated with dupilumab, the relief time of pruritus was 0-3 days (0.5, 7) days, and the pruritus was significantly alleviated after 2 weeks (t = 15.925, p < .001). The DLQI score decreased from (25.5 ± 2.5) before treatment, to (11.8 ± 4.4) at 2 weeks (t = 10.764, p < .001) and (2.1 ± 1.9) at 12 weeks (t = 30.038, p < .001). The patients had high eosinophil counts, high serum IgE levels, low serum total protein levels, and abnormal blood coagulation function. The aforementioned indicators gradually returned to normal after treatment. No adverse reactions occurred during the treatment. Conclusion: Dupilumab can effectively control the condition of bullous pemphigoid, efficiently relieve pruritus symptoms, and is relatively safe.
Treatment of Bullous Pemphigoid With Dupilumab: A Case Series of 30 Patients

Austinn C Miller,Laurie A Temiz,Susuana Adjei,Miguel A Duran,Jeffrey Sassmannshausen,Arturo Dominguez,Cristina Thomas,Jimmy D Schmidt,Michael Bernhardt,Coley J Doolittle-Amieva,Ata S Moshiri,Anthony J Thompson,Penelope Pyoung Kim-Lim,Alexzandra V Mattia,Stephen K Tyring

DOI: https://doi.org/10.36849/JDD.8258

2024-06-01

Abstract:Bullous pemphigoid is often difficult to treat with the limited therapies available. Here, we describe clinical outcomes among 30 adults with bullous pemphigoid patients treated with dupilumab. We performed a multicenter, retrospective case series between March 2020 to August 2022. Patients received a loading dose of dupilumab 600 mg, followed by 300 mg maintenance dose with varying administration frequency tailored to individual patient response. All patients experienced at least some improvement in blister formation and pruritus, with 23 (76.7%) of patients demonstrating either complete clearance of blistering or marked response. Complete clearance of pruritus or marked response was noted in 25 (83.3%) of patients. Eight patients were effectively maintained solely on dupilumab. One (3.3%) patient reported an injection site reaction. Thirty patients represent a small sample, however, to our knowledge, this is the second largest group of BP treated with dupilumab. Furthermore, we provide an understandable framework for clinicians outside of academics to follow and assess treatment responses in their BP patients treated with dupilumab. Dupilumab should be considered as a therapeutic option in patients with bullous pemphigoid given its ability to induce sustained blistering and pruritus response in both typical and refractory cases while maintaining a favorable safety profile. J Drugs Dermatol. 2024;23(6):e144-e148. doi:10.36849/JDD.8258e.
Dupilumab combined with low-dose systemic steroid therapy improves efficacy and safety for bullous pemphigoid

Jin Yang,Haiqing Gao,Zhen Zhang,Chang Tang,Zihua Chen,Lanting Wang,Fanping Yang,Shengan Chen,Shan He,Shutao Liu,Lin Tang,Yu Xu,Yao Hu,Li Ma,Ying Zhao,Xiaoqun Luo

DOI: https://doi.org/10.1111/dth.15648

2022-01-01

Dermatologic Therapy

Abstract:Routine systemic therapy for bullous pemphigoid (BP) has been challenged due to the inevitably adverse effects. According to the successful applications of dupilumab in BP cases reported, therefore, we investigate the real-life efficacy and safety of dupilumab combined with low-dose oral steroid for BP. A cohort of BP patients who received either dupilumab plus low-dose methylprednisolone (dupilumab group) or merely methylprednisolone (control group) was retrospectively reviewed. The time to disease control was investigated. Additionally, the control dose and cumulative dosage of steroids, Bullous Pemphigoid Disease Area Index (BPDAI) scores, pruritus scores, and adverse events were assessed. A total of 40 patients, with 20 in each group, were retrospectively studied. The time to disease control was shorter in the dupilumab group than the control group (14 days vs. 19 days, p = 0.043). When the disease was controlled, the control dose and cumulative dosage of methylprednisolone in the dupilumab group were substantially lower than those of the control (24.6 mg vs. 48.8 mg, 376.8 mg vs. 985.6 mg, both p < 0.01). Compared with the control, the percentage change from baseline in BPDAI scores and pruritus scores were both significantly reduced, and the adverse events were also less frequent in the dupilumab group. The combination therapy of dupilumab plus low-dose methylprednisolone exhibits superior efficacy and safety in comparison with the current first-line systemic therapy for BP.
Case report: Dupilumab for the treatment of bullous pemphigoid

Mengxin Wang,Juan Wang,Bingjun Shi

DOI: https://doi.org/10.1111/dth.15541

Abstract:Bullous pemphigoid (BP) is an inflammatory subepidermal blistering disease with rising prevalence in the elderly individuals. Cytokines associated with Th2-type immune response play an important role in the pathogenesis of BP. The traditional glucocorticoids and immunosuppressants are recommended as first-line drugs, but their therapeutic use is limited by numerous adverse effects. Dupilumab is a humanized monoclonal antibody that targets IL-4 and IL-13. It has recently been approved for the treatment of atopic dermatitis and may be an attractive therapeutic option for BP as well. Herein, we report two cases of BP treated with dupilumab. It was effective and well tolerated. Further research is needed to assess the efficacy of dupilumab in BP patients.
Dupilumab effectively and rapidly treats bullous pemphigoid by inhibiting the activities of multiple cell types

Tianmeng Yan,Yinghan Xie,Yuhua Liu,Ying Shan,Xiaoyan Wu,Jing Wang,Ya-Gang Zuo,Zhenying Zhang

DOI: https://doi.org/10.3389/fimmu.2023.1194088

2023-07-27

Abstract:Background: Bullous pemphigoid (BP) is an autoimmune skin-blistering disease. Systemic corticosteroids remain the first line treatment for moderate-to-severe BP with the potential for severe adverse events. Dupilumab has emerged as an alternative option for BP patients. Objective: We evaluated the efficiency and safety of dupilumab on BP treatment and explored a mode of drug action in depth. Methods and results: A multicenter retrospective cohort included 20 BP patients who received dupilumab with or without systemic corticosteroid in dupilumab group, and 20 matched BP patients who received corticosteroid alone in conventional group. Serum samples were collected from 20 patients (10 from dupilumab group and 10 from conventional group) at baseline and week 4. Compared to systemic corticosteroid alone, dupilumab with or without systemic corticosteroid was similarly efficacious in clinical remission at week4 (complete remission plus partial remission: 100%) and week24 (complete remission plus partial remission:100%), but allowing significant decreases in the cumulative doses of corticosteroids with reducing the incidence of adverse events. However, dupilumab did not decrease BP180 antibody despite an obvious clinical improvement. Comparative plasma proteomic analysis performed before and after treatment in 3 BP patients from dupilumab group revealed that drug use was associated with 30 differentially expressed proteins, including 26 down-regulated and 4 up-regulated proteins. The former consisted of immune related proteins involved in T/B cell interactions (inducible T-cell co-stimulator ligand, ICOSL) and in the activation of eosinophils (PRG2), mast cells (S100A12), and complement (CR2). TARC and ICOSL levels correlated with BP severity in patients who received either dupilumab or conventional treatment. Conclusion: Dupilumab has similar efficacy in treating BP as conventional drugs, by inhibiting the activities of many types of immune cells and complement, and regulating the interactions between T and B cells.
Use of dupilumab for recalcitrant bullous pemphigoid: A case report

Jillian Lamb,Kerri Purdy,Ashley Sutherland

DOI: https://doi.org/10.1177/2050313X241274855

2024-08-22

Abstract:Bullous pemphigoid is an autoimmune blistering disease affecting the dermo-epidermal junction, most commonly seen in older patients. First-line treatment includes systemic, topical corticosteroids and/or steroid-sparing immunosuppressants. Treatment with these medications may be limited by their safety profile. Dupilumab is a humanized monoclonal antibody targeting interleukin-4 and interleukin-13 cytokines currently indicated for moderate-to-severe atopic dermatitis, severe asthma, chronic rhinosinusitis with nasal polyposis, and moderate-to-severe prurigo nodularis. We report a case of a patient with recalcitrant bullous pemphigoid effectively treated with dupilumab.
The Treatment of Refractory Atypical Bullous Pemphigoid with Generalized Eczema and Intense Pruritus with Dupilumab

Wei Li,Sheng Cai,Xiao‐Yong Man

DOI: https://doi.org/10.1111/dth.15243

2021-01-01

Dermatologic Therapy

Abstract:The data that support the findings of this study are available from the corresponding author upon reasonable request.
Successful treatment of bullous pemphigoid with dupilumab: a case and brief review of the literature

Maleck Saleh,Matthew Reedy,Helen Torok,Joshua Weaver

2021-04-15

Abstract:Bullous pemphigoid is an autoimmune skin disease that results in formation of pruritic blisters. Most cases are treated with a combination of systemic and topical corticosteroids as well as other immunomodulatory drugs. Dupilumab is a fully human monoclonal antibody that acts as an antagonist against IL4Ra traditionally used in the treatment of atopic dermatitis. We present an 80-year-old man with moderate to severe bullous pemphigoid successfully treated with dupilumab.
The efficacy and safety of dupilumab combined with methylprednisolone in the treatment of bullous pemphigoid in China

Wang Qi,Xia Rushan

DOI: https://doi.org/10.1016/j.intimp.2023.110050

Abstract:We access the safety and efficacy of methylprednisolone combined with dupilumab in treating the bullous pemphigoid. 27 patients were enrolled, of which 9 received dupilumab in addition to methylprednisolone (dupilumab group, D group), while the other 18 patients were administered methylprednisolone alone (traditional group, T group). The median time to stop the formation of the new blister was 5.5 days (3.5-11.75 days) and 10 days (9-15 days) in the D group and the T group, respectively (p = 0.032). Additionally, the median time of complete healing reached was 21 days (16.25-31 days) and 29 days (25-50 days) in the D group and the T group, separately (p = 0.042). The median amount of cumulative methylprednisolone at the time of disease control was 240 mg (140-580 mg) and 460 mg (400-840 mg) in the D group and the T group, respectively (p = 0.031). The total amount of the methylprednisolone used at the time of complete healing reached was 792 mg (597-1,488.5 mg) in the D group while that was 1,370 mg (1,000-2,570 mg) in the T group (p = 0.028). No adverse event associated with dupilumab was recorded. Methylprednisolone in combination with dupilumab appeared superior to methylprednisolone alone in control of disease progression and the methylprednisolone-sparing effect.
Laboratory Safety of Dupilumab, and Its Effect on Inflammatory Biomarkers, in Chinese Adults with Moderate-to-Severe Atopic Dermatitis: an Analysis of a Randomized, Double-Blind Phase III Study

Yan Zhao,Liming Wu,Qianjin Lu,Xinghua Gao,Xiaohong Zhu,Xu Yao,Linfeng Li,Wei Li,Yangfeng Ding,Zhiqiang Song,Lingling Liu,Ningning Dang,Chunlei Zhang,Xiaoming Liu,Jun Gu,Jinyan Wang,Songmei Geng,Quanzhong Liu,Yifeng Guo,Dong Lv,Hong Ren,Xiumin Yang,Danqi Deng,Shanshan Li,Xiuping Han,Zhenshu Biao,Min Zheng,Lichee Dong,Huijuan Su,Lili Bai,John T. O'Malley,Junxiang Luo,Yi Li,Min Wang,Xinli Fan,Jianzhong Zhang

DOI: https://doi.org/10.1097/jd9.0000000000000264

2022-01-01

International Journal of Dermatology and Venereology

Abstract:Objective: Limited information is available on the use of dupilumab for the treatment of atopic dermatitis (AD) in the Chinese population. Methods: We analyzed laboratory data from a previously published randomized, double-blind phase III trial (NCT03912259) to provide further insight into the safety of dupilumab in Chinese adults with moderate to severe AD. The trial participants received either 300 mg of dupilumab or placebo every 2 weeks for 16 weeks. Hematology, blood chemistry, serum thymus and activation-regulated chemokine (TARC), and total immunoglobulin E (IgE) were evaluated. Results: In total, 82 participants received dupilumab and 83 received placebo. With the exception of eosinophil counts of >0.8 × 109/L, which were found less frequently with dupilumab (9.8%) than with placebo (18.7%), the hematology and blood chemistry values were generally stable in both treatment groups. There were no clinically significant differences between the dupilumab and placebo groups, and no participants developed treatment-emergent abnormalities of potential clinical significance. However, compared with placebo, greater decreases in serum lactate dehydrogenase (mean change, −97.4 vs. −33.5 IU/L), TARC (median percent change, −78.6% vs. −30.8%), and total IgE (median percent change, −53.4% vs. −0.2%) were observed with dupilumab than placebo at week 16. Conclusion: Dupilumab demonstrated a favorable laboratory safety profile in Chinese adults with moderate to severe AD.
Anti-interleukin 4 receptor α antibody for the treatment of Chinese bullous pemphigoid patients with diverse comorbidities and a 1-year follow-up: a monocentric real-world study

Si-Hang Wang,Ying Shan,Si-Zhe Li,Ya-Gang Zuo

DOI: https://doi.org/10.3389/fimmu.2023.1165106

IF: 7.3

2023-07-20

Frontiers in Immunology

Abstract:Background Bullous pemphigoid (BP) is a common subepidermal bullous disorder that lacks adequate treatment alternatives. Dupilumab, an anti-interleukin (IL) 4 receptor α antibody blocking Th2 molecules IL-4 and 13, has been used off-label and shown to be effective in refractory BP cases. Methods BP patients with various disease severities and comorbidities were included in this case series. All patients received dupilumab alone or in combination with immunosuppressants in a real-world setting. Complete remission (CR) was defined as the absence of pruritus symptoms and previous BP eruptions, with only hyperpigmentation patches and without newly occurring lesions for at least 4 weeks. Disease relapse was classified as the appearance of three or more new lesions within 1 month or at least one large urticarial or eczematous lesion that did not resolve within a week. Findings Ten individuals were enrolled in this case series. Pruritus symptoms and BP eruptions improved significantly in nine patients (90%). Seven patients (70%) attained CR, including all mild-to-moderate (100%) cases and three of six (50%) severe BP cases. At the dupilumab monotherapy stage, eosinophilia was observed in two severe cases. One patient out of seven (14.3%) relapsed after 1 year of follow-up after CR. Conclusion Treatment of BP with diverse comorbidities with anti-IL-4 receptor α antibody provides further credentials to a prospective randomized study. More impressive efficacy and safety profiles were observed in patients with mild-to-moderate disease after 1 year of follow-up. Eosinophilia may occur in patients receiving dupilumab monotherapy.

immunology
Dupilumab successfully treated refractory bullous pemphigoid with early clinical manifestations imitating atopic dermatitis: A case letter

Yihua Zhang,Jing Zhang,Jiawen Chen,Mengting Lin,Ting Gong,Bo Cheng,Chao Ji

DOI: https://doi.org/10.1111/ajd.13692

2021-08-26

Australasian Journal of Dermatology

Abstract:The authors confirm that the data supporting the findings of this study are available within the article and/or its supplementary materials.

dermatology
Effect of Dupilumab on Generalized Verrucosis in Refractory Bullous Pemphigoid

WANG Qijun,RUAN Yue,GUO Fei,ZHU Haiqin,PAN Meng,Qijun Wang,Yue Ruan,Fei Guo,Haiqin Zhu,Meng Pan

DOI: https://doi.org/10.2340/actadv.v103.12324

2023-09-14

Abstract:Abstract is missing (Short communication)

dermatology
Refractory bullous pemphigoid with prurigo nodularis successfully treated with dupilumab monotherapy

Po-Ta Lai,Han-Chi Tseng

DOI: https://doi.org/10.4103/1027-8117.357999

2022-12-28

Dermatologica Sinica

Abstract:Po-Ta Lai, Han-Chi Tseng Dermatologica Sinica 2022 40(4):237-238

dermatology
Fast itch relief during dupilumab predicts clinical efficacy in bullous pemphigoid, a retrospective cohort study

Jeivicaa Thevan,Eloi Schmauch,Jakob Nilsson,Carole Florence Guillet,Andrea Boesch,Lukas Krähenbühl,Barbara Meier-Schiesser,Peter Schmid-Grendelmeier,Thomas Kündig,Antonios G.A. Kolios

DOI: https://doi.org/10.1159/000540590

2024-07-29

Dermatology

Abstract:Introduction: Dupilumab has emerged as a promising treatment option for bullous pemphigoid (BP). Rapid identification of responders could avoid the need of additional immunosuppressive treatments that are associated with increased morbidity and mortality. Methods: To investigate the course of itch as an early indicator of treatment response, data of 12 BP patients treated with dupilumab at the University Hospital of Zurich were retrospectively evaluated. Disease severity was assessed by bullous pemphigoid disease area index (BPDAI) and pruritus by a numeric rating scale (NRS, 0-10) at baseline, day 1, 3, 14, month 1, 2 and last follow-up. Results: 8/12 patients (67%) had complete, and 4/12 patients (33%) had partial response during dupilumab treatment. Notably, a highly significant reduction of pruritus (p < 0.0001) was observed already on day 1 with further improvement at later time points. Moreover, fast relief of itch could predict treatment response with a significant correlation to clinical response on day 14 (Spearman correlation R 0.70, p-value 0.025), with a positive but non-significant trend on day 3 (R 0.63, p-value 0.091). Additionally, 92% (11/12 patients) were on dupilumab monotherapy at last follow-up without any concomitant systemic or topical treatment for BP. Conclusions: The rapid and significant decline in BP-associated pruritus observed with dupilumab correlated significantly with disease remission. Early evaluation of pruritus response could change how bullous pemphigoid is treated in the future and avoid additional immunosuppressive treatment in BP.

dermatology
Quick Treatment of Very Severe Refractory Hand and Foot Eczema with Dupilumab: A Case Report and Literature Review

Yali Li,Jialing Xiao,Yi Sun,Hong Fang,Jianjun Qiao

DOI: https://doi.org/10.2147/jaa.s399340

2023-01-01

Journal of Asthma and Allergy

Abstract:Previously case reports showed dupilumab may benefit for hand eczema treatment, but relatively comprehensive assessments are lacking. A 45-year-old male with multiple severe vesicles, bullae and pustule on the palmar aspects of both hand and foot diagnosed dyshidrotic eczema by pathology was treated with dupilumab at an initial dose of 600 mg subcutaneously, followed by 300 mg every 2 weeks. The physician's assessment of the patient revealed an excellent response to the treatment with dupilumab; the lesions and symptoms achieved dramatic improvement on the third day, and at 6 weeks, the hands and feet became completely normal without relapse in the past 1.5 years of discontinuation. Systematic literature searches were performed, and 6 case reports, 5 case series, 2 prospective observational studies and 1 retrospective review with a total of 150 patients were identified to describing the evaluation of efficacy and safety of dupilumab treatment for hand and foot eczema. Dupilumab appears to be safe and well tolerated with clinical benefit in recalcitrant hand and foot eczema. Larger randomized controlled trials using validated outcome measures and detailed hand eczema type and population classification are needed before dupilumab can be applied in clinical settings.

Evaluation of Dupilumab in Patients With Bullous Pemphigoid

Long-term efficacy and safety of dupilumab for severe bullous pemphigoid: A prospective cohort study

Efficacy and safety of dupilumab in the treatment of 21 cases of bullous pemphigoid: a retrospective study

A Systematic Evaluation of Dupilumab for Bullous Pemphigoid Treatment

Real-World Evaluation of the Effectiveness and Safety of Dupilumab in Bullous Pemphigoid: An Ambispective Multicenter Case Series

Concomitant use of dupilumab with glucocorticoid in bullous pemphigoid reduces disease severity: A preliminary study

Treatment of Bullous Pemphigoid With Dupilumab: A Case Series of 30 Patients

Dupilumab combined with low-dose systemic steroid therapy improves efficacy and safety for bullous pemphigoid

Case report: Dupilumab for the treatment of bullous pemphigoid

Dupilumab effectively and rapidly treats bullous pemphigoid by inhibiting the activities of multiple cell types

Use of dupilumab for recalcitrant bullous pemphigoid: A case report

The Treatment of Refractory Atypical Bullous Pemphigoid with Generalized Eczema and Intense Pruritus with Dupilumab

Successful treatment of bullous pemphigoid with dupilumab: a case and brief review of the literature

The efficacy and safety of dupilumab combined with methylprednisolone in the treatment of bullous pemphigoid in China

Laboratory Safety of Dupilumab, and Its Effect on Inflammatory Biomarkers, in Chinese Adults with Moderate-to-Severe Atopic Dermatitis: an Analysis of a Randomized, Double-Blind Phase III Study

Anti-interleukin 4 receptor α antibody for the treatment of Chinese bullous pemphigoid patients with diverse comorbidities and a 1-year follow-up: a monocentric real-world study

Dupilumab successfully treated refractory bullous pemphigoid with early clinical manifestations imitating atopic dermatitis: A case letter

Effect of Dupilumab on Generalized Verrucosis in Refractory Bullous Pemphigoid

Refractory bullous pemphigoid with prurigo nodularis successfully treated with dupilumab monotherapy

Fast itch relief during dupilumab predicts clinical efficacy in bullous pemphigoid, a retrospective cohort study

Quick Treatment of Very Severe Refractory Hand and Foot Eczema with Dupilumab: A Case Report and Literature Review